Weight Loss Drug Developer BioAge Seeks up to $602M Valuation in U.S. IPO
Is the Federal Reserve starting an interest rate cut cycle on the cusp of a wave, possibly revealing the outcome of the election in advance?
Taking history as a lesson, in an election year with declining interest rates, the probability of the incumbent president or challenger winning is greater.
RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals Analyst Ratings
AIM ImmunoTech Sees Promising Results in Ampligen Combo for Pancreatic Cancer
Thermo Fisher Scientific Hosts 2024 Investor Day, Showcasing Industry-Leading Businesses, Proven Growth Strategy, And Strong Long-Term Financial Outlook
Vanda Slips as FDA Rejects Therapy for Stomach Condition
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Looking Into Vertex Pharmaceuticals's Recent Short Interest
AstraZeneca Fasenra Gains Additional Indication
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Unpacking the Latest Options Trading Trends in Eli Lilly
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings